By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aurinia (Formerly Known as Isotechnika Pharma Inc.) 

5120 - 75th Street

Edmonton  Alberta  T6E 6W2  Canada
Phone: 780-487-1600 Fax: 780-484-4105


Key Statistics

Ownership: Public

Web Site: Aurinia
Symbol: AUPH

Company News
Aurinia (AUPH) Doses First Patient In AURORA Phase III Clinical Trial Of Voclosporin In Lupus Nephritis 5/18/2017 9:00:15 AM
Aurinia (AUPH) Reports First Quarter 2017 Financial Results, Announces Initiation Of Phase III Aurora Clinical Trial, And Provides Operational Highlights 5/15/2017 8:52:10 AM
Pharma Industry Veteran Dr. George Milne Joins Aurinia (AUPH)’s Board Of Directors 5/9/2017 9:33:01 AM
Aurinia (AUPH) Releases Additional 48-Week Data From The AURA-LV Study During Late-Breaking Session At National Kidney Foundation 2017 Spring Clinical Meetings 4/21/2017 6:15:35 AM
Aurinia (AUPH) Completes Licensing Deal With Merck Animal Health For Its Nanomicellar Formulation Of Voclosporin For The Treatment Of Canine Dry Eye Syndrome 4/18/2017 7:11:59 AM
Aurinia (AUPH) To Host Investor Event And Webcast On April 20th In Orlando, FL 4/11/2017 6:46:32 AM
Aurinia (AUPH) Announces Development Plans For Voclosporin In Europe And Japan 4/7/2017 7:50:50 AM
Aurinia (AUPH) Highlights 48-Week Data From Open-Label AURION Study At 12th International Congress On SLE (LUPUS 2017) & The 7th Asian Congress On Autoimmunity (ACA 2017) 3/27/2017 6:33:28 AM
Aurinia (AUPH) Closes US$173.1 Million Public Offering Of Common Shares And Full Exercise Of Underwriters' Option To Purchase Additional Common Shares 3/21/2017 6:57:54 AM
Aurinia (AUPH) Announces Presentation At 12th International Congress On SLE (LUPUS 2017) & The 7th Asian Congress On Autoimmunity (ACA 2017) 3/17/2017 6:36:11 AM